GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
A Phase 2, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Sponsor: Genexine, Inc.
Listed as NCT05191784, this PHASE2 trial focuses on Recurrent Glioblastoma and remains ongoing. Sponsored by Genexine, Inc., it has been updated 8 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Dec 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE2
First recorded
Jan 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genexine, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .